Slovakia

Key Insights

1
No psychedelic therapy is approved for routine patient use in Slovakia; access is limited to standard controlled medicines, with esketamine appearing only in specialist psychiatric contexts.
2
Slovakia has 3 registered trials, 0 active, and the pipeline is narrowly concentrated on esketamine versus placebo; there are 0 research organisations in the database.
3
A notable local signal is the Bratislava/University Hospital Martin esketamine work, including a 2025 Bratislava Medical Journal paper on personalised clinical monitoring.
4
Momentum is thin: the field currently depends on isolated esketamine studies, with no active trials or known Slovak psychedelic research centre to anchor expansion.

Medical Only (Private)

Reimbursed Care Access

Slovakia maintains a restrictive statutory regime for classic psychedelic compounds: most serotonergic psychedelics (psilocybin, MDMA, DMT, 5‑MeO‑DMT, mescaline, 2C‑X, ibogaine, ayahuasca) are controlled under the national narcotics statute with no authorised outpatient medical program outside clinical research. Separately, esketamine (Spravato) holds an EU marketing authorisation but — after national health-technology assessment — has not been fully accepted onto Slovakia's public reimbursement lists; ketamine remains an authorised and routinely used anaesthetic (and is used off‑label in private/academic settings for psychiatric indications), but such off‑label psychiatric uses are generally not covered by public insurance and are delivered out‑of‑pocket or within research.

Full guide →